Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & Health

Executive Summary

• Izotropic Corporation announced that its proposed Casablanca‑based subsidiary, Izotropic Africa, is in partnership discussions with Morocco’s Mohammed VI Foundation for Science & Health (FM6SS) to advance clinical research, regulatory approval and localized manufacturing of the IzoView Breast CT Imaging System.
• Under a Letter Agreement, Izotropic will hold a 40% fully diluted interest in Izotropic Africa (the remaining 60% held by a local Business Group), with a target to finalize a formal agreement by April 30 2026.
• As part of the discussions, an IzoView device valued at US$500 k will be placed at a leading Moroccan hospital at no cost to serve as a clinical research site.

Key Details

• Letter Agreement Ownership: Izotropic – 40% fully diluted; Business Group – 60% fully diluted (subject to final corporate, tax, regulatory and legal structuring).
• Geographic Scope: Licensing, marketing and distribution of IzoView Breast CT and follow‑on products across Africa and the Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE).
• Partnership Focus with FM6SS:
• Clinical research collaborations in Morocco.
• Support for regulatory advancement of IzoView Breast CT.
• Evaluation of localized manufacturing and assembly opportunities within Morocco.
• Device Placement: One IzoView Breast CT system, valued at US$500 k, to be installed at a leading Moroccan hospital free of charge as a clinical research site.
• Timeline: Parties intend to negotiate in good faith and execute a Formal Agreement no later than April 30 2026.
• Moroccan National Framework (2026‑2030): Highlights government incentives—VAT exemptions, 15‑year business tax holidays, 5‑year corporate tax reductions—to encourage domestic medical‑device manufacturing, reinforcing the strategic relevance of Izotropic Africa’s initiatives.

Notable Quotes

(No direct quotes were provided in the release.)